PepGen Inc. (PEPG)
| Market Cap | 179.38M +105.6% |
| Revenue (ttm) | n/a |
| Net Income | -71.94M |
| EPS | -1.19 |
| Shares Out | 69.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 514,270 |
| Open | 2.680 |
| Previous Close | 2.680 |
| Day's Range | 2.585 - 2.720 |
| 52-Week Range | 1.310 - 7.800 |
| Beta | 1.97 |
| Analysts | Strong Buy |
| Price Target | 10.19 (+293.44%) |
| Est. Earnings | Nov 11, 2026 |
About PEPG
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Bo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for PEPG stock is "Strong Buy." The 12-month stock price target is $10.19, which is an increase of 293.44% from the latest price.
News
PepGen reports Q2 EPS (26c), consensus (29c)
“During the second quarter, our team maintained a strong focus on execution as we advanced FREEDOM2 and continued preparing for our next clinical data readout,” said James McArthur, PhD, President…
PepGen to advance PGN-EDODM1 into highest dose cohort
PepGen (PEPG) announced that an independent Data and Safety Monitoring Board, DSMB, has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study evaluating PGN-EDODM1 in participants with myotonic...
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights.
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review.
PepGen Quarterly report: Q2 2026
PepGen has published its Q2 2026 quarterly earnings report on August 6, 2026.
PepGen Earnings release: Q2 2026
PepGen released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
PepGen Slides: Company presentation
PepGen has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Craig-Hallum bullish on PepGen, initiates with a Buy
As previously reported, Craig-Hallum analyst Adam Vodel initiated coverage of PepGen (PEPG) with a Buy rating and $11 price target The firm views PepGen as a high-risk but highly asymmetric…
PepGen initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Adam Vodel initiated coverage of PepGen (PEPG) with a Buy rating and $11 price target
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen files $400M mixed securities shelf
12:08 EDT PepGen (PEPG) files $400M mixed securities shelf
PepGen Registration statement: Registration filing
PepGen filed a registration statement on May 18, 2026, providing details about a securities offering with the SEC.
PepGen price target lowered to $4 from $5 at Wedbush
Wedbush analyst Laura Chico lowered the firm’s price target on PepGen (PEPG) to $4 from $5 and keeps an Outperform rating on the shares. Most important in the Q1 update…
PepGen reports Q1 EPS (26c), consensus (31c)
“We made encouraging progress during the first quarter of 2026 in our FREEDOM2-DM1 trial. The 5 mg/kg cohort – the initial dose cohort – demonstrated a favorable tolerability profile and…
PepGen sees cash runway into 2H27
Cash, Cash Equivalents and Marketable Securities were $132.3 million as of March 31, 2026. Based on currently planned operations, the Company believes that its existing cash, cash equivalents, and mar...
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Quarterly report: Q1 2026
PepGen has published its Q1 2026 quarterly earnings report on May 12, 2026.
PepGen Earnings release: Q1 2026
PepGen released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
PepGen Slides: Company presentation
PepGen has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
PepGen Proxy statement: Proxy filing
PepGen filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
PepGen Proxy statement: Proxy filing
PepGen filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
PepGen Slides: Company presentation
PepGen has posted slides in relation to its latest quarterly earnings report, which was published on April 17, 2026.
PepGen Transcript: Study update
The phase II FREEDOM2 study's lowest dose cohort (5 mg/kg) showed a favorable safety profile and promising splicing and vHOT improvements, with one rare outlier affecting group averages. Dose escalation to 10 mg/kg is underway, with results expected in H2 2026.
PepGen Press release: Study update
PepGen issued a press release on March 31, 2026, disclosing material business information to investors.
PepGen Slides: Study update
PepGen has posted slides in relation to its latest quarterly earnings report, which was published on March 31, 2026.